NYSE:COV (COV) (COV) Stock Price, News & Analysis → World’s biggest multibillionaire investor is buying THIS by the ton [picture] (From Stansberry Research) (Ad) Free COV Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Share Share Today's Range N/A50-Day Range N/A52-Week Range N/AVolumeN/AAverage Volume3.88 million shsMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get (COV) alerts: Email Address Ad Stansberry ResearchWorld’s biggest multibillionaire investor is buying THIS by the ton [picture]Don't Buy Bullion or Mining Stocks. Do THIS Instead As gold continues to break all-time highs, many folks will run out and buy bullion or mining stocks. That's not the best way to ride this gold bull market higher. Note, this showed a 995% gain the last time we shared this same investment idea.Click here to find out what to do. About (COV) Stock (NYSE:COV)Covidien Public Limited Company is a healthcare products company. The Company is engaged in the development, manufacture and sale of healthcare products for use in clinical and home settings. The Company’s brands include Kendall, Nellcor, Puritan Bennett and Valleylab, among others. It has a presence in more than 70 countries, with products sold in over 150 countries. The Company’s segments include Medical Devices and United States Medical Supplies. Medical Devices includes marketing of advanced and general surgical solutions, peripheral vascular and neurovascular therapies, patient monitoring products, and airway and ventilation products. United States Medical Supplies includes products, such as nursing care, medical surgical, SharpSafety and original equipment manufacturer (OEM) products. The Company’s products include Surgical Solutions, Vascular Therapies, Respiratory and Patient Care.Read More Ad Stansberry ResearchWorld’s biggest multibillionaire investor is buying THIS by the ton [picture]Don't Buy Bullion or Mining Stocks. Do THIS Instead As gold continues to break all-time highs, many folks will run out and buy bullion or mining stocks. That's not the best way to ride this gold bull market higher. Note, this showed a 995% gain the last time we shared this same investment idea.Click here to find out what to do. COV Stock News HeadlinesApril 24, 2024 | yahoo.comScientists report longest known ‘extreme’ Covid infection in 72-year-old manApril 24, 2024 | msn.comEngineers muffle invading pathogens with a 'molecular mask'April 25, 2024 | Stansberry Research (Ad)World’s biggest multibillionaire investor is buying THIS by the ton [picture]Don't Buy Bullion or Mining Stocks. Do THIS Instead As gold continues to break all-time highs, many folks will run out and buy bullion or mining stocks. That's not the best way to ride this gold bull market higher. Note, this showed a 995% gain the last time we shared this same investment idea.April 24, 2024 | msn.comCOVID-19 virus disrupts protein production: Researcher discusses her recent findingsApril 24, 2024 | msn.comNew tARC-seq method enhances precision in tracking SARS-CoV-2 mutationsApril 24, 2024 | msn.comRepurposed nasal antibiotic neomycin shows promise in preventing and treating respiratory viral infectionsApril 24, 2024 | msn.comInfluenza is considered the biggest pandemic threatApril 24, 2024 | msn.comGlobal study reveals mismatch in COVID-19 treatment guidelines with WHO standardsApril 25, 2024 | Stansberry Research (Ad)World’s biggest multibillionaire investor is buying THIS by the ton [picture]Don't Buy Bullion or Mining Stocks. Do THIS Instead As gold continues to break all-time highs, many folks will run out and buy bullion or mining stocks. That's not the best way to ride this gold bull market higher. Note, this showed a 995% gain the last time we shared this same investment idea.April 23, 2024 | msn.comOptimal timing maximizes Paxlovid benefits for treating COVID-19April 23, 2024 | msn.comHow B cells recognize new variants of SARS-CoV-2April 23, 2024 | msn.comDoes diabetes increase the risk of long COVID?April 23, 2024 | msn.comStudy discovers hidden mechanism behind rapid COVID variantsApril 22, 2024 | msn.comMan Utd: Neville makes ‘extreme’ Ten Hag sack claim; Carragher insists Cov display ‘cost’ him jobApril 22, 2024 | msn.comNew technology uncovers mechanism affecting generation of new COVID variantsApril 21, 2024 | msn.comThe next pandemic lurks, and we must be ready for itApril 21, 2024 | msn.comNew study rates Influenza as the top pandemic threat, here’s whyApril 20, 2024 | msn.comStudy shows experts rate influenza as the number one pathogen of concern of pandemic potentialApril 19, 2024 | msn.comEx-Fauci adviser shared ‘confidential’ NIH info with EcoHealth about COVID biosafety levels: docsApril 19, 2024 | msn.comLongest case of COVID-19 was breeding ground for mutations, study showsApril 19, 2024 | usnews.comDozens of COVID Virus Mutations Arose in Man With Longest Known CaseApril 19, 2024 | theglobeandmail.comClosing Bell: CI Hlth Care Giants Cov Call ETF flat on Wednesday (FHI-B)April 18, 2024 | bloomberg.comCovid Patient’s Infection Lasts Record 613 Days and Spawns New MutationsApril 18, 2024 | msn.comLungs Of Young Adults More Susceptible To Covid-19 Causing SARS-CoV-2 Virus, Claims StudyApril 17, 2024 | msn.comNew vaccine promises broad protection against SARS-CoV-2 and other sarbecovirusesApril 17, 2024 | msn.comArboviruses, mosquitoes and potential hosts tracked in real time in São Paulo cityApril 17, 2024 | msn.com7 out of 10 Americans think COVID-19 came from a labSee More Headlines Receive COV Stock News and Ratings via Email Sign-up to receive the latest news and ratings for (COV) and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/05/2014Today4/25/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSE SectorN/A Industry N/A Sub-IndustryHealth Care Equipment Current SymbolNYSE:COV CUSIPG2554F11 CIK1385187 WebN/A Phone+353-1-4381700FaxN/AEmployeesN/AYear FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable BetaN/A 10 Best Stocks to Own in 2024Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2024 and why they should be in your portfolio. Get This Free Report Key ExecutivesGary L. Ellis (Age 61)President, Chief Executive Officer Charles J. Dockendorff (Age 63)Chief Financial Officer, Executive Vice President Bryan C. Hanson (Age 50)Group President, Covidien John H. Masterson (Age 54)Senior Vice President, General Counsel Michael P. Dunford (Age 54)Senior Vice President - Human Resources James C. Clemmer (Age 53)Senior Vice President and President - Medical Supplies Business Amy A. McBride-Wendell (Age 53)Senior Vice President - Strategy and Business Development Jacqueline F. Strayer (Age 58)Senior Vice President-Corporate Communications Michael E. Tarnoff (Age 46)Senior Vice President,Chief Medical Officer Peter L. Wehrly (Age 57)Senior Vice President, Group President - Developed Markets More Executives COV Stock Analysis - Frequently Asked Questions How were (COV)'s earnings last quarter? (COV) (NYSE:COV) issued its quarterly earnings results on Wednesday, November, 5th. The healthcare company reported $1.15 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.02 by $0.13. The healthcare company earned $2.73 billion during the quarter, compared to analyst estimates of $2.69 billion. The firm's quarterly revenue was up 6.8% on a year-over-year basis. During the same period in the previous year, the business posted $0.91 earnings per share. What other stocks do shareholders of (COV) own? Based on aggregate information from My MarketBeat watchlists, some companies that other (COV) investors own include Pfizer (PFE), Chevron (CVX), Intel (INTC), Johnson & Johnson (JNJ), Boeing (BA), CVS Health (CVS), EMC (EMC), Gilead Sciences (GILD) and JPMorgan Chase & Co. (JPM). This page (NYSE:COV) was last updated on 4/25/2024 by MarketBeat.com Staff From Our PartnersThe Best AI Stock to Own in the World Today is Trading for Just $25Banyan Hill PublishingConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThis Apple-like Innovator is Revolutionizing HealthcareWall Street StarThe A.I. story nobody is telling you (Read ASAP)TradeSmithRed Alert: Your Money's Disappearance Act - Banks' Greed Unleashed!Priority GoldHe Is Giving Away BitcoinCrypto Swap Profitstop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyYour Money is Not SafeAmerican Alternative Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding (COV) Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
